MARK2 and non-small cell lung carcinoma: 1. Significantly downregulated in NSCLC; sponges miR-130b-3p to relieve inhibition on serine/threonine kinase STK11; 2. Further inhibits transcription and translation of PD-L1, reduces PD-L1 expression on tumor cell surface, and restores CD8+T cell infiltration and killing activity